tetano
Editor, Senior Moderator
Microbiol Spectr
. 2024 Feb 1:e0356323.
doi: 10.1128/spectrum.03563-23. Online ahead of print. Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)
Matthew G Johnson[SUP] 1 [/SUP], Julie M Strizki[SUP] 1 [/SUP], Erin Jensen[SUP] 1 [/SUP], Jonathan Cohen[SUP] 2 [/SUP], Christine Katlama[SUP] 3 4 [/SUP], Roman Fishchuk[SUP] 5 [/SUP], Alfredo Ponce-de-León[SUP] 6 [/SUP], Nyda Fourie[SUP] 7 [/SUP], Chien-Yu Cheng[SUP] 8 [/SUP], Dorothy McCoy[SUP] 1 [/SUP], Mary Vesnesky[SUP] 1 [/SUP], Carmelle T Norice[SUP] 1 [/SUP], Ying Zhang[SUP] 1 [/SUP], Angela Williams-Diaz[SUP] 1 [/SUP], Michelle L Brown[SUP] 1 [/SUP], Patricia Carmelitano[SUP] 1 [/SUP], Jay A Grobler[SUP] 1 [/SUP], Amanda Paschke[SUP] 1 [/SUP], Carisa De Anda[SUP] 1 [/SUP]
Affiliations
This exploratory post hoc analysis assessed the incidence of respiratory viral coinfections and their impact on clinical outcomes in non-hospitalized adults with mild-to-moderate coronavirus disease-2019 (COVID-19) treated with molnupiravir versus placebo for 5 days in the Phase 2/3 MOVe-OUT trial (NCT04575597), which took place in October 2020 to January 2021 (Phase 2, n = 302) and May 2021 to October 2021 (Phase 3, n = 1,433). Among 1,735 total randomized participants, 1,674 had a baseline respiratory pathogen panel (NxTAG Respiratory Pathogen Panel for the Luminex MAGPIX instrument) performed and 69 (4.1%) were coinfected with at least one additional respiratory viral pathogen. Human rhinovirus/enterovirus (39/69, 56.5%) was the most common coinfection detected at baseline. In the modified intention-to-treat population, two participants with coinfecting respiratory RNA viruses were hospitalized and received respiratory interventions through Day 29, and none died; one participant in the molnupiravir group was coinfected with human rhinovirus/enterovirus, and one participant in the placebo group was coinfected with human metapneumovirus. Hospitalization or death occurred in 6.2% and 9.0% of non-coinfected participants in the molnupiravir versus placebo group, respectively, and over 90% did not require respiratory interventions. Most coinfecting respiratory RNA viruses detected at baseline were not detected at the end of therapy in both the molnupiravir and placebo groups. In summary, participants coinfected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and another respiratory RNA virus were not more likely to be hospitalized or die, or require respiratory interventions, compared to participants who were not coinfected with another respiratory RNA virus at baseline in both groups.IMPORTANCERespiratory viral coinfections are known to occur with coronavirus disease-2019 (COVID-19). In a cohort of non-hospitalized adults with mild-to-moderate COVID-19 treated with molnupiravir versus placebo in the MOVe-OUT trial during October 2020 to October 2021, 4.1% of participants had a documented viral coinfection; human rhinovirus/enterovirus was the most common pathogen detected with the NxTAG Respiratory Pathogen Panel assay. Participants who had a coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and another respiratory RNA virus were not more likely to have worse clinical outcomes compared to those participants without a viral coinfection, and many coinfecting respiratory RNA viruses were no longer detected at the end of the 5-day treatment period in both groups.
Keywords: COVID-19; epidemiology; molnupiravir; respiratory pathogens.
. 2024 Feb 1:e0356323.
doi: 10.1128/spectrum.03563-23. Online ahead of print. Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)
Matthew G Johnson[SUP] 1 [/SUP], Julie M Strizki[SUP] 1 [/SUP], Erin Jensen[SUP] 1 [/SUP], Jonathan Cohen[SUP] 2 [/SUP], Christine Katlama[SUP] 3 4 [/SUP], Roman Fishchuk[SUP] 5 [/SUP], Alfredo Ponce-de-León[SUP] 6 [/SUP], Nyda Fourie[SUP] 7 [/SUP], Chien-Yu Cheng[SUP] 8 [/SUP], Dorothy McCoy[SUP] 1 [/SUP], Mary Vesnesky[SUP] 1 [/SUP], Carmelle T Norice[SUP] 1 [/SUP], Ying Zhang[SUP] 1 [/SUP], Angela Williams-Diaz[SUP] 1 [/SUP], Michelle L Brown[SUP] 1 [/SUP], Patricia Carmelitano[SUP] 1 [/SUP], Jay A Grobler[SUP] 1 [/SUP], Amanda Paschke[SUP] 1 [/SUP], Carisa De Anda[SUP] 1 [/SUP]
Affiliations
- PMID: 38299867
- DOI: 10.1128/spectrum.03563-23
This exploratory post hoc analysis assessed the incidence of respiratory viral coinfections and their impact on clinical outcomes in non-hospitalized adults with mild-to-moderate coronavirus disease-2019 (COVID-19) treated with molnupiravir versus placebo for 5 days in the Phase 2/3 MOVe-OUT trial (NCT04575597), which took place in October 2020 to January 2021 (Phase 2, n = 302) and May 2021 to October 2021 (Phase 3, n = 1,433). Among 1,735 total randomized participants, 1,674 had a baseline respiratory pathogen panel (NxTAG Respiratory Pathogen Panel for the Luminex MAGPIX instrument) performed and 69 (4.1%) were coinfected with at least one additional respiratory viral pathogen. Human rhinovirus/enterovirus (39/69, 56.5%) was the most common coinfection detected at baseline. In the modified intention-to-treat population, two participants with coinfecting respiratory RNA viruses were hospitalized and received respiratory interventions through Day 29, and none died; one participant in the molnupiravir group was coinfected with human rhinovirus/enterovirus, and one participant in the placebo group was coinfected with human metapneumovirus. Hospitalization or death occurred in 6.2% and 9.0% of non-coinfected participants in the molnupiravir versus placebo group, respectively, and over 90% did not require respiratory interventions. Most coinfecting respiratory RNA viruses detected at baseline were not detected at the end of therapy in both the molnupiravir and placebo groups. In summary, participants coinfected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and another respiratory RNA virus were not more likely to be hospitalized or die, or require respiratory interventions, compared to participants who were not coinfected with another respiratory RNA virus at baseline in both groups.IMPORTANCERespiratory viral coinfections are known to occur with coronavirus disease-2019 (COVID-19). In a cohort of non-hospitalized adults with mild-to-moderate COVID-19 treated with molnupiravir versus placebo in the MOVe-OUT trial during October 2020 to October 2021, 4.1% of participants had a documented viral coinfection; human rhinovirus/enterovirus was the most common pathogen detected with the NxTAG Respiratory Pathogen Panel assay. Participants who had a coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and another respiratory RNA virus were not more likely to have worse clinical outcomes compared to those participants without a viral coinfection, and many coinfecting respiratory RNA viruses were no longer detected at the end of the 5-day treatment period in both groups.
Keywords: COVID-19; epidemiology; molnupiravir; respiratory pathogens.